The ScipherIx platform identifies subsets of patient populations within a certain disease, clearly showing that patients cannot be treated uniformly. We develop ScipherDx tests to identify the groups of patients who will not respond to certain drugs so they can be prescribed alternative therapies. ScipherRx finds new targets to help treat specific groups of patients who do not respond to drugs currently on the market.
PrismRA identifies rheumatoid arthritis patients who will not respond to anti-TNFs
PrismUC predicts non-response to anti-TNFs for patients with ulcerative colitis
Both tests have been shown to identify at least half of patients who will not respond to anti-TNFs with at least 90% accuracy – performance requirements set by rheumatologists and gastroenterologists.